Actively Recruiting

Age: 18Years - 99Years
All Genders
ID06657846

Health-Related Quality of Life and Financial Toxicity in Patients With VEXAS Syndrome: An Italian GIMEMA Study

Led by Gruppo Italiano Malattie EMatologiche dell'Adulto · Updated on 2025-07-15

100

Participants Needed

17

Research Sites

13 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a multicenter observational study to describe the health-related quality of life (HRQoL) and symptom profiles of adult patients with VEXAS syndrome. The study also aims to investigate financial toxicity and how well patients tolerate treatments. To provide context, the data collected from VEXAS patients will be compared with a matched group of patients with myelodysplastic syndromes (MDS). The overall goal is to create benchmark HRQoL data that can support future prospective studies and help design clinical trials. Participants will complete quality of life questionnaires, including the EORTC QLQ-C30 and FACIT-Fatigue assessments, at a single time point after enrolling in the study. There are no drug treatments or interventions being tested, as this is an observational study focused on assessing patient-reported outcomes and financial impacts. The study collects data at one time only, without follow-up treatment phases. During the study, participants will provide information through questionnaires that assess their quality of life, fatigue levels, and financial burdens related to their condition. Researchers will analyze these results by age and sex groups and compare them with matched patients who have MDS. The study is expected to end in September 2025, and all data collection occurs at study entry without long-term follow-up.

CONDITIONS

Brief Title

HRQoL and Financial Toxicity in Patients With VEXAS Syndrome

Who Can Participate

Age: 18Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients (≥ 18 years old) with a confirmed diagnosis of VEXAS syndrome (UBA1 pathogenic mutation detected)
  • Written informed consent
Not Eligible

You will not qualify if you...

  • Having any kind of psychiatric disorder or major cognitive dysfunction
  • Not able to read and understand local language

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 1 day

Participants complete quality of life and financial toxicity questionnaires to assess their health-related quality of life and treatment tolerability.

1 visit (in-person)

Long-term Monitoring

Duration - Up to study completion

Participants are observed to establish benchmark data on health-related quality of life and financial toxicity.

No additional visits required

Trial Site Locations

Total: 17 locations

1

Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica

Ancona, Italy

Actively Recruiting

2

Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia

Bergamo, Italy

Actively Recruiting

3

Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia

Bologna, Italy

Actively Recruiting

4

Asst Degli Spedali Civili Di Brescia - Uo Ematologia

Brescia, Italy

Actively Recruiting

5

Istituto Di Candiolo - Fondazione Del Piemonte Per L'Oncologia - Irccs - Centro Trapianti

Candiolo, Italy

Actively Recruiting

6

Aou Careggi - Firenze - Sod Ematologia

Florence, Italy

Actively Recruiting

7

Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora

Milan, Italy

Actively Recruiting

8

Irccs Ospedale S. Raffaele - Milano - Uo Oncoematologia

Milan, Italy

Actively Recruiting

9

Aou Federico Ii - Napoli - Uoc Ematologia

Naples, Italy

Actively Recruiting

10

Aou Di Padova - Uo Ematologia

Padova, Italy

Actively Recruiting

11

Fondazione Ircss Policlinico San Matteo - Pavia - Uo Ematologia

Pavia, Italy

Actively Recruiting

12

Ausl Di Reggio Emilia - Arcispedale Santa Maria Nuova, Irccs - Sc Ematologia

Reggio Emilia, Italy

Actively Recruiting

13

Aou Policlinico Tor Vergata - Roma - Uoc Trapianto Cellule Staminali

Roma, Italy

Actively Recruiting

14

Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia

Rozzano, Italy

Actively Recruiting

15

Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - Ematologia

San Giovanni Rotondo, Italy

Not Yet Recruiting

16

Ospedale Mauriziano Umberto I - Torino - Scdu Ematologia

Torino, Italy

Actively Recruiting

17

Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia

Verona, Italy

Actively Recruiting

Loading map...

Research Team

F

Fabio Efficace

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase 1 Study of Pacritinib in Vacuoles, E1 Ubiqutin-activ...

E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here